Eli Lilly’s $6.5B Houston Mega-Plant: Reshoring Pharmaceutical API Manufacturing and Scaling the Oral GLP-1 Revolution
In September 2026, global pharmaceutical powerhouse Eli Lilly and Company officially broke ground on an unprecedented $6.5 billion advanced medicine […]